

# Tobias Engel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1981983/publications.pdf>

Version: 2024-02-01

98  
papers

4,961  
citations

87843

38  
h-index

98753

67  
g-index

102  
all docs

102  
docs citations

102  
times ranked

5287  
citing authors

#	ARTICLE	IF	CITATIONS
1	Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. <i>Nature Medicine</i> , 2012, 18, 1087-1094.	15.2	423
2	Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. <i>European Journal of Neuroscience</i> , 2007, 25, 81-86.	1.2	300
3	Full Reversal of Alzheimer's Disease-Like Phenotype in a Mouse Model with Conditional Overexpression of Glycogen Synthase Kinase-3. <i>Journal of Neuroscience</i> , 2006, 26, 5083-5090.	1.7	234
4	Chronic lithium administration to FTDP-17 tau and GSK-3 $\beta$ overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. <i>Journal of Neurochemistry</i> , 2006, 99, 1445-1455.	2.1	197
5	miRNA Expression Profile after Status Epilepticus and Hippocampal Neuroprotection by Targeting miR-132. <i>American Journal of Pathology</i> , 2011, 179, 2519-2532.	1.9	194
6	Seizure suppression and neuroprotection by targeting the purinergic P2X7 receptor during status epilepticus in mice. <i>FASEB Journal</i> , 2012, 26, 1616-1628.	0.2	173
7	MicroRNAs in Neurodegenerative Diseases. <i>International Review of Cell and Molecular Biology</i> , 2017, 334, 309-343.	1.6	151
8	Unilateral hippocampal CA3-predominant damage and short latency epileptogenesis after intra-amygdala microinjection of kainic acid in mice. <i>Brain Research</i> , 2008, 1213, 140-151.	1.1	137
9	Increased neocortical expression of the P2X7 receptor after status epilepticus and anticonvulsant effect of P2X7 receptor antagonist A $\beta$ 438079. <i>Epilepsia</i> , 2013, 54, 1551-1561.	2.6	130
10	Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody. <i>ELife</i> , 2018, 7, .	2.8	128
11	Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy. <i>Journal of Neuroscience</i> , 2016, 36, 5920-5932.	1.7	127
12	Reduced Mature MicroRNA Levels in Association with Dicer Loss in Human Temporal Lobe Epilepsy with Hippocampal Sclerosis. <i>PLoS ONE</i> , 2012, 7, e35921.	1.1	121
13	Cooexpression of FTDP-17 tau and GSK-3 $\beta$ in transgenic mice induce tau polymerization and neurodegeneration. <i>Neurobiology of Aging</i> , 2006, 27, 1258-1268.	1.5	105
14	Antagomirs targeting microRNA-134 increase hippocampal pyramidal neuron spine volume in vivo and protect against pilocarpine-induced status epilepticus. <i>Brain Structure and Function</i> , 2015, 220, 2387-2399.	1.2	101
15	microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus. <i>Scientific Reports</i> , 2015, 5, 17486.	1.6	98
16	CHOP regulates the p53-MDM2 axis and is required for neuronal survival after seizures. <i>Brain</i> , 2013, 136, 577-592.	3.7	95
17	ATPergic signalling during seizures and epilepsy. <i>Neuropharmacology</i> , 2016, 104, 140-153.	2.0	86
18	The ATP-Gated P2X7 Receptor As a Target for the Treatment of Drug-Resistant Epilepsy. <i>Frontiers in Neuroscience</i> , 2017, 11, 21.	1.4	83

#	ARTICLE	IF	CITATIONS
19	MicroRNA-Mediated Downregulation of the Potassium Channel Kv4.2 Contributes to Seizure Onset. <i>Cell Reports</i> , 2016, 17, 37-45.	2.9	71
20	Reduced hippocampal damage and epileptic seizures after <i>status epilepticus</i> in mice lacking proapoptotic Puma. <i>FASEB Journal</i> , 2010, 24, 853-861.	0.2	65
21	Proteins and microRNAs are differentially expressed in tear fluid from patients with Alzheimerâ€™s disease. <i>Scientific Reports</i> , 2019, 9, 15437.	1.6	63
22	<i>In vivo</i> Contributions of BH3-Only Proteins to Neuronal Death Following Seizures, Ischemia, and Traumatic Brain Injury. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 1196-1210.	2.4	61
23	P2X7 Receptor Inhibition Interrupts the Progression of Seizures in Immature Rats and Reduces Hippocampal Damage. <i>CNS Neuroscience and Therapeutics</i> , 2014, 20, 556-564.	1.9	58
24	Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models. <i>PLoS ONE</i> , 2016, 11, e0156468.	1.1	57
25	Contribution of apoptosis-associated signaling pathways to epileptogenesis: lessons from Bcl-2 family knockouts. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 110.	1.8	54
26	Neurodevelopmental alterations and seizures developed by mouse model of infantile hypophosphatasia are associated with purinergic signalling deregulation. <i>Human Molecular Genetics</i> , 2016, 25, 4143-4156.	1.4	54
27	Regulation of P2X7 receptor expression and function in the brain. <i>Brain Research Bulletin</i> , 2019, 151, 153-163.	1.4	54
28	Apoptosis, Bcl-2 family proteins and caspases: the ABCs of seizure-damage and epileptogenesis?. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2009, 1, 97-115.	0.8	54
29	Bax Regulates Neuronal Ca <sup>2+</sup> Homeostasis. <i>Journal of Neuroscience</i> , 2015, 35, 1706-1722.	1.7	52
30	Expression and function of the metabotropic purinergic P2Y receptor family in experimental seizure models and patients with drugâ€™refractory epilepsy. <i>Epilepsia</i> , 2017, 58, 1603-1614.	2.6	51
31	Protective neuronal induction of ATF5 in endoplasmic reticulum stress induced by status epilepticus. <i>Brain</i> , 2013, 136, 1161-1176.	3.7	49
32	NMDA receptorâ€™mediated excitotoxic neuronal apoptosis <i>in vitro</i> and <i>in vivo</i> occurs in an ER stress and PUMA independent manner. <i>Journal of Neurochemistry</i> , 2008, 105, 891-903.	2.1	47
33	Bok Is Not Pro-Apoptotic But Suppresses Poly ADP-Ribose Polymerase-Dependent Cell Death Pathways and Protects against Excitotoxic and Seizure-Induced Neuronal Injury. <i>Journal of Neuroscience</i> , 2016, 36, 4564-4578.	1.7	47
34	ATP and adenosineâ€™Two players in the control of seizures and epilepsy development. <i>Progress in Neurobiology</i> , 2021, 204, 102105.	2.8	47
35	P2X receptors as targets for the treatment of status epilepticus. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 237.	1.8	45
36	ATP release during seizures â€™ A critical evaluation of the evidence. <i>Brain Research Bulletin</i> , 2019, 151, 65-73.	1.4	45

#	ARTICLE	IF	CITATIONS
37	Effects of P2X7 receptor antagonists on hypoxia-induced neonatal seizures in mice. <i>Neuropharmacology</i> , 2017, 116, 351-363.	2.0	44
38	Transgenic Overexpression of 14-3-3 Zeta Protects Hippocampus against Endoplasmic Reticulum Stress and Status Epilepticus In Vivo. <i>PLoS ONE</i> , 2013, 8, e54491.	1.1	44
39	P2X purinoceptors as a link between hyperexcitability and neuroinflammation in status epilepticus. <i>Epilepsy and Behavior</i> , 2015, 49, 8-12.	0.9	42
40	Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment. <i>Biomolecules</i> , 2019, 9, 734.	1.8	41
41	A systems approach delivers a functional microRNA catalog and expanded targets for seizure suppression in temporal lobe epilepsy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 15977-15988.	3.3	41
42	Inherent P2X7 Receptors Regulate Macrophage Functions during Inflammatory Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 232.	1.8	39
43	Context-Specific Switch from Anti- to Pro-epileptogenic Function of the P2Y <sub>1</sub> Receptor in Experimental Epilepsy. <i>Journal of Neuroscience</i> , 2019, 39, 5377-5392.	1.7	37
44	The Metabotropic Purinergic P2Y Receptor Family as Novel Drug Target in Epilepsy. <i>Frontiers in Pharmacology</i> , 2018, 9, 193.	1.6	36
45	P2X7 receptor in epilepsy; role in pathophysiology and potential targeting for seizure control. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2012, 4, 174-87.	0.8	36
46	Spatio-temporally restricted blood-brain barrier disruption after intra-amygdala kainic acid-induced status epilepticus in mice. <i>Epilepsy Research</i> , 2013, 103, 167-179.	0.8	35
47	Genome-wide microRNA profiling of plasma from three different animal models identifies biomarkers of temporal lobe epilepsy. <i>Neurobiology of Disease</i> , 2020, 144, 105048.	2.1	35
48	Elevated p53 and lower MDM2 expression in hippocampus from patients with intractable temporal lobe epilepsy. <i>Epilepsy Research</i> , 2007, 77, 151-156.	0.8	34
49	Bi-directional genetic modulation of GSK-3 $\beta$ exacerbates hippocampal neuropathology in experimental status epilepticus. <i>Cell Death and Disease</i> , 2018, 9, 969.	2.7	32
50	Characterization of the Expression of the ATP-Gated P2X7 Receptor Following Status Epilepticus and during Epilepsy Using a P2X7-EGFP Reporter Mouse. <i>Neuroscience Bulletin</i> , 2020, 36, 1242-1258.	1.5	32
51	A calcium-sensitive feed-forward loop regulating the expression of the ATP-gated purinergic P2X7 receptor via specificity protein 1 and microRNA-22. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 255-266.	1.9	31
52	Tau Phosphorylation in a Mouse Model of Temporal Lobe Epilepsy. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 308.	1.7	29
53	Antagonizing Increased miR-135a Levels at the Chronic Stage of Experimental TLE Reduces Spontaneous Recurrent Seizures. <i>Journal of Neuroscience</i> , 2019, 39, 5064-5079.	1.7	28
54	MicroRNA-22 Controls Aberrant Neurogenesis and Changes in Neuronal Morphology After Status Epilepticus. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 442.	1.4	26

#	ARTICLE	IF	CITATIONS
55	Tau phosphorylation in hippocampus results in toxic gain-of-function. <i>Biochemical Society Transactions</i> , 2010, 38, 977-980.	1.6	24
56	BH3-only protein Bid is dispensable for seizure-induced neuronal death and the associated nuclear accumulation of apoptosis-inducing factor. <i>Journal of Neurochemistry</i> , 2010, 115, 92-101.	2.1	24
57	Bi-lateral changes to hippocampal cholesterol levels during epileptogenesis and in chronic epilepsy following focal-onset status epilepticus in mice. <i>Brain Research</i> , 2012, 1480, 81-90.	1.1	23
58	Spatiotemporal progression of ubiquitin-proteasome system inhibition after status epilepticus suggests protective adaptation against hippocampal injury. <i>Molecular Neurodegeneration</i> , 2017, 12, 21.	4.4	23
59	Circulating P2X7 Receptor Signaling Components as Diagnostic Biomarkers for Temporal Lobe Epilepsy. <i>Cells</i> , 2021, 10, 2444.	1.8	23
60	Mitochondrial localization of the Forkhead box class O transcription factor FOXO3a in brain. <i>Journal of Neurochemistry</i> , 2013, 124, 749-756.	2.1	21
61	Elevated blood purine levels as a biomarker of seizures and epilepsy. <i>Epilepsia</i> , 2021, 62, 817-828.	2.6	21
62	Increased expression of the ATP-gated P2X7 receptor reduces responsiveness to anti-convulsants during status epilepticus in mice. <i>British Journal of Pharmacology</i> , 2022, 179, 2986-3006.	2.7	20
63	Bcl-2 homology domain 3-only proteins Puma and Bim mediate the vulnerability of CA1 hippocampal neurons to proteasome inhibition <i>in vivo</i> . <i>European Journal of Neuroscience</i> , 2011, 33, 401-408.	1.2	19
64	Genetic deletion of microRNA-22 blunts the inflammatory transcriptional response to status epilepticus and exacerbates epilepsy in mice. <i>Molecular Brain</i> , 2020, 13, 114.	1.3	18
65	High concordance between hippocampal transcriptome of the mouse intra-amygdala kainic acid model and human temporal lobe epilepsy. <i>Epilepsia</i> , 2020, 61, 2795-2810.	2.6	17
66	Effects of transient focal cerebral ischemia in mice deficient in puma. <i>Neuroscience Letters</i> , 2009, 451, 237-240.	1.0	16
67	Looking for novel functions of tau. <i>Biochemical Society Transactions</i> , 2012, 40, 653-655.	1.6	16
68	RNA sequencing of synaptic and cytoplasmic Upf1-bound transcripts supports contribution of nonsense-mediated decay to epileptogenesis. <i>Scientific Reports</i> , 2017, 7, 41517.	1.6	16
69	Differential Expression of the Metabotropic P2Y Receptor Family in the Cortex Following Status Epilepticus and Neuroprotection via P2Y1 Antagonism in Mice. <i>Frontiers in Pharmacology</i> , 2019, 10, 1558.	1.6	16
70	Targeting Neuroinflammation via Purinergic P2 Receptors for Disease Modification in Drug-Refractory Epilepsy. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3367-3392.	1.6	16
71	Haploinsufficient TNAP Mice Display Decreased Extracellular ATP Levels and Expression of Pannexin-1 Channels. <i>Frontiers in Pharmacology</i> , 2018, 9, 170.	1.6	14
72	Deviant reporter expression and P2X4 passenger gene overexpression in the soluble EGFP BAC transgenic P2X7 reporter mouse model. <i>Scientific Reports</i> , 2020, 10, 19876.	1.6	11

#	ARTICLE	IF	CITATIONS
73	Polyadenylation of mRNA as a novel regulatory mechanism of gene expression in temporal lobe epilepsy. <i>Brain</i> , 2020, 143, 2139-2153.	3.7	11
74	Progressive Mitochondrial SOD1G93A Accumulation Causes Severe Structural, Metabolic and Functional Aberrations through OPA1 Down-Regulation in a Mouse Model of Amyotrophic Lateral Sclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8194.	1.8	10
75	Beyond Seizure Control: Treating Comorbidities in Epilepsy via Targeting of the P2X7 Receptor. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2380.	1.8	10
76	A mouse model to study tau pathology related with tau phosphorylation and assembly. <i>Journal of the Neurological Sciences</i> , 2007, 257, 250-254.	0.3	7
77	Distinct behavioral and epileptic phenotype differences in 129/P mice compared to C57BL/6 mice subject to intraamygdala kainic acid-induced status epilepticus. <i>Epilepsy and Behavior</i> , 2016, 64, 186-194.	0.9	6
78	P2X7 Receptor-Dependent microRNA Expression Profile in the Brain Following Status Epilepticus in Mice. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 127.	1.4	6
79	Functional P2X <sub>7</sub> Receptors in the Auditory Nerve of Hearing Rodents Localize Exclusively to Peripheral Glia. <i>Journal of Neuroscience</i> , 2021, 41, 2615-2629.	1.7	6
80	Tubby-like protein 1 (Tulp1) is a target of microRNA-134 and is down-regulated in experimental epilepsy. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2017, 9, 178-187.	0.8	6
81	Characterization of Alzheimer paired helical filaments by electron microscopy. <i>Microscopy Research and Technique</i> , 2005, 67, 121-125.	1.2	5
82	Tau Kinase I Overexpression Induces Dentate Gyrus Degeneration. <i>Neurodegenerative Diseases</i> , 2010, 7, 13-15.	0.8	5
83	Neonatal Seizures and Purinergic Signalling. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7832.	1.8	5
84	Editorial: P2X7 as Common Therapeutic Target in Brain Diseases. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 656011.	1.4	5
85	Overexpression of 14-3-3 $\sigma$ Increases Brain Levels of C/EBP Homologous Protein CHOP. <i>Journal of Molecular Neuroscience</i> , 2015, 56, 255-262.	1.1	4
86	Detecting Circulating MicroRNAs as Biomarkers in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2018, 1779, 471-484.	0.4	4
87	Pembrolizumab plus axitinib and nivolumab plus ipilimumab as first-line treatments of advanced intermediate- or poor-risk renal-cell carcinoma: a number needed to treat analysis from the Brazilian private perspective. <i>Journal of Medical Economics</i> , 2021, 24, 291-298.	1.0	4
88	Novel Point-of-Care Diagnostic Method for Neonatal Encephalopathy Using Purine Nucleosides. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 732199.	1.4	4
89	De-repression of myelin-regulating gene expression after status epilepticus in mice lacking the C/EBP homologous protein CHOP. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2014, 6, 185-98.	0.8	4
90	Analyzing the Role of the P2X7 Receptor in Epilepsy. <i>Methods in Molecular Biology</i> , 2022, , 367-387.	0.4	4

#	ARTICLE	IF	CITATIONS
91	Excitotoxicity induced by kainic acid provokes glycogen synthase kinase-3 truncation in the hippocampus. <i>Brain Research</i> , 2015, 1611, 84-92.	1.1	3
92	Targeting the proteasome in epilepsy. <i>Oncotarget</i> , 2017, 8, 45042-45043.	0.8	3
93	Deletion of the BH3-only protein Noxa alters electrographic seizures but does not protect against hippocampal damage after status epilepticus in mice. <i>Cell Death and Disease</i> , 2018, 8, e2556-e2556.	2.7	2
94	Purinergic signaling as a target for emerging neurotherapeutics. <i>Brain Research Bulletin</i> , 2019, 151, 1-2.	1.4	2
95	Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2018, 10, 172-183.	0.8	2
96	Purinergic signaling-induced neuroinflammation and status epilepticus. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 735-737.	1.4	1
97	Animal Models with Modified Expression of GSK-3 for the Study of Its Physiology and of Its Implications in Human Pathologies. , 0, , 203-219.		0
98	Using Amperometric, Enzyme-Based Biosensors for Performing Longitudinal Measurements of Extracellular Adenosine 5-Triphosphate in the Mouse. <i>Methods in Molecular Biology</i> , 2020, 2041, 197-207.	0.4	0